Literature DB >> 9283711

Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine.

D Crespi1, T Mennini, M Gobbi.   

Abstract

1. The mechanism underlying 5-hydroxytryptamine (5-HT) and/or dopamine release induced by (+)-amphetamine ((+)-Amph), 3,4-methylendioxymethamphetamine (MDMA), p-chloroamphetamine (pCA) and (+)-fenfluramine ((+)-Fen) was investigated in rat brain superfused synaptosomes preloaded with the 3H neurotransmitters. 2. Their rank order of potency for [3H]-5-HT-releasing activity was the same as for inhibition of 5-HT uptake (pCA > or = MDMA > or = (+)-Fen > > (+)-Amph). Similarly, their rank order as [3H]-dopamine releasers and dopamine uptake inhibitors was the same ((+)-Amph > > pCA = MDMA > > (+)-Fen). We also confirmed that the release induced by these compounds was prevented by selective transporter inhibitors (indalpine or nomifensine). 3. [3H]-5HT and/or [3H]-dopamine release induced by all these compounds was partially (31-80%), but significantly Ca(2+)-dependent. Lack of extracellular Ca2+ did not alter uptake mechanisms nor did it modify the carrier-dependent dopamine-induced [3H]-dopamine release. (+)-Amph-induced [3H]-dopamine release and pCA- and MDMA-induced [3H]-5-HT release were significantly inhibited by omega-agatoxin-IVA, a specific blocker of P-type voltage-operated Ca(2+)-channels, similar to the previous results on (+)-Fen-induced [3H]-5-HT release. 4. Methiothepin inhibited the Ca(2+)-dependent component of (+)-Amph-induced [3H]-dopamine release with high potency (70 nM), as previously found with (+)-Fen-induced [3H]-5-HT release. The inhibitory effect of methiothepin was not due to its effects as a transporter inhibitor or Ca(2+)-channel blocker and is unlikely to be due to its antagonist properties on 5-HT1/2, dopamine or any other extracellular receptor. 5. These results indicate that the release induced by these compounds is both 'carrier-mediated' and Ca(2+)-dependent (possibly exocytotic-like), with the specific carrier allowing the amphetamines to enter the synaptosome. The Ca(2+)-dependent release is mediated by Ca(2+)-influx (mainly through P-type Ca(2+)-channels), possibly triggered by the drug interacting with an unknown intracellular target, affected by methiothepin, common to both 5-HT and dopamine synaptosomes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9283711      PMCID: PMC1564879          DOI: 10.1038/sj.bjp.0701325

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

Review 1.  Synaptosomes still viable after 25 years of superfusion.

Authors:  L Raiteri; M Raiteri
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

2.  Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain.

Authors:  Samanta Yubero-Lahoz; Mario A Ayestas; Bruce E Blough; John S Partilla; Richard B Rothman; Rafael de la Torre; Michael H Baumann
Journal:  Eur J Pharmacol       Date:  2011-11-03       Impact factor: 4.432

Review 3.  Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA).

Authors:  J R Docherty
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

4.  Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 map kinase pathway.

Authors:  Pierre Brown; Charles R Gerfen
Journal:  J Comp Neurol       Date:  2006-09-20       Impact factor: 3.215

5.  Concurrent Inhibition of Vesicular Monoamine Transporter 2 Does Not Protect Against 3,4-Methylenedioxymethamphetamine (Ecstasy) Induced Neurotoxicity.

Authors:  Aram B Cholanians; Andy V Phan; Serrine S Lau; Terrence J Monks
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

6.  Sensitizing regimens of (+/-)3, 4-methylenedioxymethamphetamine (ecstasy) elicit enduring and differential structural alterations in the brain motive circuit of the rat.

Authors:  K T Ball; C L Wellman; E Fortenberry; G V Rebec
Journal:  Neuroscience       Date:  2009-02-21       Impact factor: 3.590

Review 7.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

8.  The anorexic agents, sibutramine and fenfluramine, depress GABA(B)-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells.

Authors:  Ada Ledonne; Luca Sebastianelli; Mauro Federici; Giorgio Bernardi; Nicola Biagio Mercuri
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

9.  The effect of quetiapine (Seroquel™) on conditioned place preference and elevated plus maze tests in rats when administered alone and in combination with (+)-amphetamine.

Authors:  Angela E McLelland; Mathew T Martin-Iverson; Richard J Beninger
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

10.  Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice.

Authors:  Stéphane Doly; Jesus Bertran-Gonzalez; Jacques Callebert; Alexandra Bruneau; Sophie Marie Banas; Arnauld Belmer; Katia Boutourlinsky; Denis Hervé; Jean-Marie Launay; Luc Maroteaux
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.